---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-007928"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:45:57.439091+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI presents Multikine data: 5yr survival 73% vs 45% control; risk of death halved

## Summary
- Multikine cut risk of death by 50% in low PD-L1 head and neck cancer patients: 73% survival vs 45% control at 5 years.
- Hazard ratio 0.35 (95% CI 0.19-0.66, log rank p=0.0015).
- Multikine targets low PD-L1 tumor expression, contrasting with checkpoint inhibitors like Keytruda.
- Company working to commence FDA confirmatory Registration Study for Multikine.

## SEC filing metadata
- accession: 0001654954-24-007928
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495424007928/0001654954-24-007928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495424007928/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-007928
- JSON: https://secwatch.observer/filing/0001654954-24-007928.json
- Plain text: https://secwatch.observer/filing/0001654954-24-007928.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.